22 results about "Dysthymic Disorder" patented technology

The invention provides a mood disorder assessment system based on multi-level feature fusion, and the system comprises a data collection unit which is used for collecting electroencephalogram signals of a plurality of brain regions of a to-be-assessed patient; the electroencephalogram feature extraction unit is used for extracting electroencephalogram features corresponding to the electroencephalogram signals of the brain regions; the multi-level feature extraction unit is constructed on the basis of the symptom features of the multiple testees and the corresponding electroencephalogram features, and is used for performing multi-level electroencephalogram feature latent variable extraction on the electroencephalogram features of the brain regions of the patient to be evaluated to obtain multi-level electroencephalogram feature latent variables; and the feature fusion and classification unit is used for carrying out classification prediction based on the electroencephalogram feature latent variables to obtain a mood disorder assessment result of the patient to be assessed. The method solves the problem that a mood disorder assessment system in the prior art adopts a single feature extraction and learning strategy and has no constraint of symptom information, so that the recognition capability of a model for mood disorders of different functional abnormality types is limited.

The present disclosure provides a crystalline form of enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating mood disorders, neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using a crystalline form of enantiopure deuterium-enriched bupropion.

The invention discloses a multi-mode mood disorder classification method based on fMRI and voice, and the method mainly aims at constructing an fMRI and voice interaction fusion network framework which is composed of three stages of network structures, namely, a double-branch feature extraction network used for carrying out the feature extraction of voice data and fMRI signals, and a multi-branch feature extraction network used for carrying out the feature extraction of the voice data and the fMRI signals. The feature interaction fusion network is used for converting the multi-modal features into fusion features containing key information of data of each modal, and the full connection layer network is used for mapping the fusion features to category probabilities. A brain network topological structure and voice features which are related to mood disorder classification tasks and have high discrimination capability are effectively extracted from fMRI and voice data; therefore, cross-modal causal association between the fMRI and the voice data is effectively mined, and high-precision and interpretable mood obstacle recognition and classification are realized.

The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as agonists or antagonists of the serotonin (5-HT2A) receptor, preferably non-hallucinogenic biased agonists at the serotonin (5-HT2A) receptor, such as having agonism biased towards the beta-arrestin signaling pathway. Such compounds are useful for the treatment of mood disorders, general anxiety, social anxiety, depression, and other neuropsychiatric diseases.

The application provides a kind of construction method of mood disorder evaluation model based on hierarchical multi-level gating, comprising: obtaining the electroencephalogram of a plurality of subjects, labeling label, constructing first training sample set;Using first training sample set for training, obtaining a plurality of electroencephalogram parameter combinations respectively corresponding time sequence dynamic graph network feature extraction model and related time sequence dynamic graph network features;Using first training sample set, time sequence dynamic graph network features to construct second training sample set, train hierarchical multi-level gating model;Based on the time sequence dynamic graph network feature extraction model corresponding to each electroencephalogram parameter combination and hierarchical multi-level gating model, obtain mood disorder evaluation model.The application solves the problem that the mood disorder evaluation model in the prior art does not consider the correlation between different parameter combinations and tasks among brain regions, frequency bands and observation time lengths, does not perform hierarchical screening of different parameter brain networks based on task correlation, resulting in limited evaluation accuracy.

Described herein, in part, are dosage forms and compositions useful for the prevention and / or treatment of diseases or conditions associated with aberrant T-type calcium channel function, such as epilepsy and epileptic syndromes (e.g., absent seizures, teenager myospastic epilepsy or genetic epilepsy), tremor (e.g., epilepsy seizures, spasmodic epilepsy, or hereditary epilepsy), or tremor (e.g., epilepsy seizures). Idiopathic tremor (e.g., idiopathic tremor) and psychiatric disorders (e.g., mood disorders (e.g., severe depressive disorder)). The invention also includes methods for modulating the function of T-type calcium channels.

The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as selective agonists or antagonists serotonin (5-HT2A) receptor, preferably non-hallucinogenic biased agonists or antagonists at the serotonin (5-HT2A) receptor, such as having agonism biased towards the beta-arrestin signaling pathway, or as serotonin (5-HT2A) receptor antagonists. Such compounds are useful for the treatment of mood disorders, general anxiety, social anxiety, depression, anhedonia, and other neuropsychiatric diseases.

The invention provides compounds of the formula (I):wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

The present disclosure provides ergoline compounds and their use in the treatment of mood disorders. Pharmaceutical compositions and methods of making various ergoline compounds are provided.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof, wherein - - - - -, R1, R2, R3a, R3b, R4a , R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Compositions consist essentially of trigonelline or consist of trigonelline. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions can be administered to a mammal to treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof. The mitochondria-related disease or condition is selected from the group consisting of deleterious effects of aging, stress (e.g., oxidative stress), obesity, overweight, reduced metabolic rate, metabolic syndrome, diabetes mellitus, complications from diabetes, hyperlipidemia, neurodegenerative disease, cognitive disorder, stress-induced or stress-related cognitive dysfunction, mood disorder, anxiety disorder, age-related neuronal death or dysfunction, chronic kidney disease, kidney failure, trauma, infection, cancer, hearing loss, macular degeneration, myopathies and dystrophies, and combinations thereof.

Provided herein are methods for treating psychiatric disorders by gene therapy (e.g. AAV-directed gene therapy) to deliver and express the human SP4 gene in neuronal cells. Treatable psychiatric disorders include schizophrenia, anxiety, obsessive compulsive disorder, or mood disorder.

The application provides a mood disorder evaluation model construction method and equipment based on electroencephalogram and symptom-oriented fusion. The method comprises the following steps: obtaining multiple mood disorder related symptom characteristics of multiple subjects; collecting electroencephalogram characteristics of multiple brain regions of each subject to construct a first training sample set; based on the first training sample set, a multi-level symptom-oriented feature extraction module is constructed, and multiple levels of electroencephalogram characteristic latent variables oriented by symptoms are obtained; based on the electroencephalogram characteristic latent variables of each level, the corresponding mood disorder diagnosis label is labeled, and then the feature fusion module and the classification module are iteratively trained; based on the multi-level symptom-oriented feature extraction module, the feature fusion module and the classification module, a mood disorder evaluation model is obtained. The application solves the problem that in the prior art, a single feature extraction and learning strategy is adopted, and there is no constraint of symptom information, resulting in limited recognition ability of the model for mood disorders of different functional abnormal types.

Described herein, in part, are dosage forms and compositions useful for the prevention and / or treatment of diseases or conditions associated with aberrant T-type calcium channel function, such as epilepsy and epileptic syndromes (e.g., absent seizures, teenager myospastic epilepsy or genetic epilepsy), tremor (e.g., epilepsy seizures, spasmodic epilepsy, or hereditary epilepsy), or tremor (e.g., epilepsy seizures). Idiopathic tremor (e.g., idiopathic tremor) and psychiatric disorders (e.g., mood disorders (e.g., severe depressive disorder)). The invention also includes methods for modulating the function of T-type calcium channels.

This article discloses a lipid prodrug of bromo-lysergic acid diethylamide (2-bromo-LSD) (2-bromo-lysergic acid diethylamide), which achieves improved pharmacokinetic properties and allows for easier long-term administration to patients. The disclosed lipid prodrug is indicated for the treatment of cluster headaches and mood disorders in human subjects.

The present disclosure relates to a method of treating a patient having a mood disorder comprising administering to a subject in need thereof a pharmaceutical composition comprising a base compound comprising substantially pure N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a pharmaceutically acceptable salt thereof in a specific dosing regimen.

The present invention provides a 19-nor-C3,3-disubstituted C21-azacyclo-substituted steroid and a method for using same. In particular, the present invention relates to a compound represented by general formula (I), a method for preparing same, a pharmaceutical composition containing the compound, and use thereof as a GABAAR positive allosteric modulator in prevention and / or treatment of various CNS-related diseases, such as treatment of sleep disorder, mood disorder, insomnia, anxiety, depression, traumatic brain injury (TBI), stress and epilepsy, etc. Substituents in the general formula (I) are defined the same as in the description.

Described herein, in part, are dosage forms and compositions useful for the prevention and / or treatment of diseases or conditions associated with aberrant T-type calcium channel function, such as epilepsy and epileptic syndromes (e.g., absent seizures, teenager myospastic epilepsy or genetic epilepsy), tremor (e.g., epilepsy seizures, spasmodic epilepsy, or hereditary epilepsy), or tremor (e.g., epilepsy seizures). Idiopathic tremor (e.g., idiopathic tremor) and psychiatric disorders (e.g., mood disorders (e.g., severe depressive disorder)). The invention also includes methods for modulating the function of T-type calcium channels.

Described herein, in part, are dosage forms and compositions useful for preventing and / or treating diseases or disorders associated with aberrant function of T-type calcium channels, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or genetic epilepsy), tremors (e.g., essential tremor), and psychiatric disorders (e.g., mood disorders (e.g., major depressive disorder)). The present invention also includes methods for modulating the function of T-type calcium channels.

The invention provides an electroencephalogram and symptom-oriented fusion mood disorder assessment model construction method and equipment. The method comprises the following steps: acquiring a plurality of mood disorder related symptom characteristics of a plurality of testees; collecting electroencephalogram characteristics of a plurality of brain regions of each testee, and constructing a first training sample set; based on the first training sample set, constructing a multi-level symptom-oriented feature extraction module, and obtaining a plurality of levels of symptom-oriented electroencephalogram feature latent variables; based on the electroencephalogram feature latent variables of each level, marking corresponding mood disorder diagnosis tags and then carrying out iterative training on the feature fusion module and the classification module; and obtaining a mood disorder evaluation model based on a multi-level symptom-oriented feature extraction module, a feature fusion module and a classification module. According to the invention, the problem that the model has limited ability to identify mood disorders of different functional abnormality types due to the adoption of a single feature extraction and learning strategy and no constraint of symptom information in the prior art is solved.

Described herein, in part, are crystalline and salt forms of N-((1-(2-(tert-butylamino)-2-oxoethyl) piperidin-4-yl) methyl)-3-chloro-5-fluorobenzamide for use in the prevention and / or treatment of diseases or conditions associated with abnormal function of T-type calcium channels, such as epilepsy and epileptic syndromes (e.g., epilepsy and epileptic syndromes). ), myoctic seizures, teenager muscular spasmodic epilepsy, or genetic epilepsy, tremor (e.g., idiopathic tremor), and mental disorders (e.g., mood disorders (e.g., severe depressive disorders).

A sensor that employs rationally designed polymeric and biopolymeric matrices by incorporating and maximizing key functional groups while eliminating interfering functional groups. A series of polymers and biopolymers designed with high aromaticity and negative charges to attract and detect monoamine redox active neurotransmitters (i.e., serotonin, dopamine, epinephrine, and norepinephrine) are disclosed and used in the disclosed sensor. Notably, these polymers and biopolymers are designed in such a way as to enable facile deposition onto surfaces either spontaneously or through quick electrodeposition. Such sensors typically employ a significantly reduced amount of PEDOT and can be used as a neurotransmitter sensor that can be used to monitor and / or diagnosis mood disorders, sleep disorders, cognition deficits, metabolite levels, neurological disorders; therapeutics level monitoring and / or identification. The aforementioned sensor can be wearable, implantable, multiuse or single use.